Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07285655 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
A Phase 3 study, sponsored by Liquidia Technologies.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 344
- Enrollment target
NCT07285655 is a Phase 3 study that is actively recruiting participants, run by Liquidia Technologies. The registered enrollment target is 344 participants.
The verdict
NCT07285655, a Phase 3 study, is actively recruiting participants, sponsored by Liquidia Technologies.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 344 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if L606 is safe and if it helps people with high blood pressure in the lungs (pulmonary hypertension) caused by interstitial lung disease (PH-ILD, WHO Group 3). One of the main ways the study will check this is by seeing if people can walk further in six minutes (called the "six-minute walk test"). Another important (secondary) goal is to see how long it takes for PH-ILD to get worse while people are taking L606. One way the study will measure this is by looking at the distance people walk at different times in the study on different doses of L606. Throughout the study, doctors will also closely monitor for any side effects people have to make sure L606 is safe. People who decide to join this study will be randomly (like tossing a coin) placed into one of two groups: one group will get L606 and the other group will get a placebo, which will look like L606 but will not contain any active medicine. At the end of the initial blinded portion of the study, study participants may have the opportunity to enroll in an open-label extension portion of the study where all participants will receive L606.
Interventions
- DRUG Placebo
- DRUG L606
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 344 participants |
| Start Date | 2026-04-23 |
| Est. Completion | 2031-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07285655
The ClinicalTrials.gov registry entry for NCT07285655 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 344 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Liquidia Technologies, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07285655 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07285655 about?
NCT07285655 is a clinical study titled "A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD". The purpose of this study is to find out if L606 is safe and if it helps people with high blood pressure in the lungs (pulmonary hypertension) caused by interstitial lung disease (PH-ILD, WHO Group 3). One of the main ways the study will check this is by seeing if people can walk further in six minu...
What is the current status of trial NCT07285655?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 344 participants. The study started on 2026-04-23. Estimated completion is 2031-12.
What interventions are being tested in trial NCT07285655?
The interventions under investigation include: Placebo (DRUG), L606 (DRUG).
Who is sponsoring clinical trial NCT07285655?
This trial is sponsored by Liquidia Technologies, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.